SavedAdd your journal

Journals / Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2026 / Volume: 13 Issue: 3

Clinical Flare-Up After Androgen Deprivation Therapy in Prostate Cancer: Incidence and Associated Factors

Ali Can Albaz(MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7725-1241
Oğuzcan Erbatu(MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-2840-0028
Oktay Üçer(MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7912-0408
Gökhan Temeltaş(MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7673-2206
Talha Muezzinoglu(MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7799-008X
Pages
—
Publication Date
2026-09-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Identifying high-risk patients before treatment initiation and implementing appropriate preventive strategies may help prevent early complications and optimize patient management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the incidence, clinical characteristics, and associated factors of clinical flare-up during the first 30 days after initiation of androgen deprivation therapy (ADT) in patients with prostate cancer.
📊
Key Findings & Data:Methods: In this retrospective single-center study, 168 patients who initiated ADT between March 2023 and March 2026 were included.
💡
Conclusion & Impact:Identifying high-risk patients before treatment initiation and implementing appropriate preventive strategies may help prevent early complications and optimize patient management.
🔬Design:Research Article
📍Scope:2023 Verileri
⚙️Variables:Prostate cancer · androgen deprivation therapy · clinical flare-up

Abstract

Objective: To evaluate the incidence, clinical characteristics, and associated factors of clinical flare-up during the first 30 days after initiation of androgen deprivation therapy (ADT) in patients with prostate cancer. Methods: In this retrospective single-center study, 168 patients who initiated ADT between March 2023 and March 2026 were included. Factors associated with clinical flare-up were evaluated using univariate logistic regression analysis. Results: Clinical flare-up occurred in 14 patients (8.3%), with most events developing during the first week after ADT initiation. Higher baseline prostate-specific antigen (PSA) levels, bone metastasis, vertebral involvement, and the presence of baseline lower urinary tract symptoms were associated with clinical flare-up. Concomitant bicalutamide use was associated with a lower risk of clinical flare-up. Conclusion: Clinical flare-up is an important early complication of ADT despite its relatively low incidence. Identifying high-risk patients before treatment initiation and implementing appropriate preventive strategies may help prevent early complications and optimize patient management.

🔖

Cite This Article

Albaz, A. C., Erbatu, O., Üçer, O., Temeltaş, G., Muezzinoglu, T. (2026). Clinical Flare-Up After Androgen Deprivation Therapy in Prostate Cancer: Incidence and Associated Factors. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Volume: 13 Issue: 3. https://doi.org/10.34087/cbusbed.2001274

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Azad, A. A., Kostos, L., Agarwal, N., Attard, G., Davis, I. D., Dorff, T., Gillessen, S., Parker, C., Smith, M. R., Sweeney, C. J., Tombal, B., & Fizazi, K. (2025). Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. European Urology, 87(4), 455–467. https://doi.org/10.1016/j.eururo.2025.01.010
  2. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
  3. Conteduca, V., Poti, G., Caroli, P., Russi, S., Brighi, N., Lolli, C., Schepisi, G., Romeo, A., Matteucci, F., Paganelli, G., Marchetti, P., & De Giorgi, U. (2021). Flare phenomenon in prostate cancer: recent evidence on new drugs and next-generation imaging. Therapeutic Advances in Medical Oncology, 13, 1758835920987654. https://doi.org/10.1177/1758835920987654
  4. George, D. J., & Dearnaley, D. P. (2021). Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. Future Oncology, 17(33), 4431–4446. https://doi.org/10.2217/fon-2021-0575 Hussain, M., Fizazi, K., Shore, N. D., Heidegger, I., Smith, M. R., Tombal, B., & Saad, F. (2024). Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncology, 10(6), 807–820. https://doi.org/10.1001/jamaoncol.2024.0591
  5. James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M.,. Xie, L. P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet, 403(10437), 1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2
  6. Lazo, A., Blanco, M., Ocanto, A., Duque-Santana, V., Del Castillo, R., Barrado, M., Zafra, J., López-Campos, F., & Couñago, F. (2025). GnRH antagonists: current evidence and role in prostate cancer. Archivos Españoles de Urología, 78(6), 642–652. https://doi.org/10.56434/j.arch.esp.urol.20257806.87
  7. Nasser, N. J., Sun, K., Scanlon, K. M., Mishra, M. V., & Molitoris, J. K. (2022). Administering docetaxel for metastatic hormone-sensitive prostate cancer 1–6 days compared to more than 14 days after the start of LHRH agonist is associated with better clinical outcomes due to androgen flare. Cancers, 14(4), 864. https://doi.org/10.3390/cancers14040864
  8. Nishimura, K. (2023). Management of bone metastasis in prostate cancer. Journal of Bone and Mineral Metabolism, 41(3), 317–326. https://doi.org/10.1007/s00774-023-01435-w
  9. Raval, A. D., Chen, S., Littleton, N., Constantinovici, N., & Goebell, P. J. (2025). Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU International, 135(3), 408–421. https://doi.org/10.1111/bju.16577
  10. Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025). Prostate cancer: a review. JAMA, 333(16), 1433–1446. https://doi.org/10.1001/jama.2025.0228
  11. Shirley, M. (2023). Relugolix: a review in advanced prostate cancer. Targeted Oncology, 18(2), 295–302. https://doi.org/10.1007/s11523-022-00944-4
  12. Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D'Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Ippolito, J. E., Karnes, R. J., Kishan, A.,. Freedman-Cass, D. (2025). Prostate cancer, version 3.2026, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 23(11), 469–493. https://doi.org/10.6004/jnccn.2025.0052
  13. Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., Gandaglia, G., Gillessen, S., Grivas, N., Henry, A. M., Lardas, M., van Leenders, G. J. L. H., Liew, M., Linares Espinos, E., Oldenburg, J.,. Cornford, P. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II—2024 update: treatment of relapsing and metastatic prostate cancer. European Urology, 86(2), 164–182. https://doi.org/10.1016/j.eururo.2024.04.010
  14. Van Poppel, H., & Abrahamsson, P. A. (2020). Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. International Journal of Urology, 27(10), 830–837. https://doi.org/10.1111/iju.14303
  15. James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M.,. Xie, L. P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet, 403(10437), 1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2
  16. Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D'Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Ippolito, J. E., Karnes, R. J., Kishan, A.,. Freedman-Cass, D. (2025). Prostate cancer, version 3.2026, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 23(11), 469–493. https://doi.org/10.6004/jnccn.2025.0052
  17. Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., Gandaglia, G., Gillessen, S., Grivas, N., Henry, A. M., Lardas, M., van Leenders, G. J. L. H., Liew, M., Linares Espinos, E., Oldenburg, J.,. Cornford, P. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II—2024 update: treatment of relapsing and metastatic prostate cancer. European Urology, 86(2), 164–182. https://doi.org/10.1016/j.eururo.2024.04.010